Lexicon Pharmaceuticals (LXRX) Change in Receivables (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Change in Receivables of $9.4 million for Q1 2026, up 1015.69% year-over-year from $842078.3 in Q1 2025, and up 18690.0% quarter-over-quarter from $50000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Change in Receivables (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 17 years of Change in Receivables data on file, last reported at $9.4 million in Q1 2026.
- Change in Receivables for Q1 2026 came in at $9.4 million, up 1015.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.3 million (up 913.25% YoY), and the FY2025 annual result was -$1.1 million, down 144.21% from the prior year.
- Change in Receivables advanced to $9.4 million in Q1 2026 per LXRX's latest filing, from $50000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $9.4 million in Q1 2026 and troughed at -$1.0 million in Q1 2025.
- A 5-year average of $692058.8 and a median of $151000.0 in 2025 frame the typical range for Change in Receivables.
- On a YoY basis, Change in Receivables climbed as much as 14200.0% in 2023 and fell as far as 6216.67% in 2023.
- A 5-year view of Change in Receivables shows it stood at -$12000.0 in 2022, then soared by 5866.67% to $692000.0 in 2023, then slipped by 16.47% to $578000.0 in 2024, then tumbled by 91.35% to $50000.0 in 2025, then surged by 18690.0% to $9.4 million in 2026.
- Business Quant data shows LXRX's Change in Receivables at $9.4 million in Q1 2026, $50000.0 in Q4 2025, and $151000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn | 9.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.40 Mn |
| Mar 31, 2026 | 9.40 Mn |
| Dec 31, 2025 | 50,000.00 |
| Dec 31, 2025 | 50,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Jun 30, 2025 | -264,000.00 |
| Jun 30, 2025 | -264,000.00 |
| Mar 31, 2025 | -1.03 Mn |
| Mar 31, 2025 | -1.03 Mn |
| Dec 31, 2024 | 578,000.00 |
| Dec 31, 2024 | 578,000.00 |
| Sep 30, 2024 | 275,000.00 |
| Sep 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 516,000.00 |
| Mar 31, 2024 | 516,000.00 |
| Dec 31, 2023 | 692,000.00 |
| Dec 31, 2023 | 692,000.00 |